This Biotech Fund Sold $8 Million, Yet Remains Bullish on Terns
A biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
This overview explains risk parity investing and how allocating risk rather than capital can influence retirement portfolio stability.
26,917 articlesA biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
As AI reshapes computing, three chip giants still worth buying offer a compelling setup for long-term investors. Expl...
Palantir's journey has been a roller coaster—massive gains, sharp pulls, and ongoing questions. This guide distills w...
Could SpaceX become a defining winner in a new era of commercial space? This guide breaks down how buying SpaceX toda...
A seasoned fund boosted its stake in ZoomInfo, revealing a confident bet on GTM's growth story. This article explains...
Investors are watching whispers about Apple and Intel teaming up. This article breaks down what that could mean for s...
Investors are weighing whether HOOD deserves a place in a modern portfolio. This guide helps you gauge signals, risks...
Vertex Pharmaceuticals just made aBold move that could reshape its growth trajectory. This guide breaks down the deal...
A new science council linked to Trump signals a stronger link between AI and crypto policy. This morning minute exami...
Sam Altman raised questions about SpaceX's bold plan for AI data centers in space. This article breaks down the viabi...
Real estate can grow wealth or burn it, depending on where you buy. Learn which markets pose the biggest risks, the s...
As AI hype climbs, one tech stock think more could offer substantial upside in the S&P 500. This article lays out the...